Dorard et al. demonstrated that the concomitant ablation of BRAF and CRAF in NRAS Q61K mutant mouse melanoma models resulted in a blockage of tumor growth, providing evidence that the MAPK pathway is an important downstream effector of oncogenicity in NRAS mutant melanomas [94]. The gene discussed is BRAF; the disease is melanoma.